 The final efficacy evaluation will be done after 6 months of treatment; Nine obligatory visits are planned Patients will be assessed at the following visits: base-line inclusion D-15, and 2, 4, ,12, ,20, 22, 24 25, 26 weeks. At the 24 W visit, the final efficacy will be performed and medication will be tapered over a maximum period of 2 weeks. The final safety assessment will be performed at 26W. 